Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab

Inclusion Criteria: * Patient informed consent must be signed before to start the study. * Age between 18 to 70 years. * Performance Status 0-1 according to ECOG scale at the moment of inclusion. * Life expectancy \>3 months. * Confirmed anatomopathologic diagnosis of local advance scaly larynx or hypolarynx carcinoma III or IV stage without evidence of distance metastasis, which surgery involve a total laryngectomy. * T3, T4A, T4B or T2 not candidate to a partial laryngectomy. In case of T2 of both locations it will be required III or IVA stage. * Patients in medical conditions to receive neoadjuvant treatment with TPF followed by hyperfractionated radiotherapy combined with cetuximab. * Presence of a injury measurable with RECIST criteria. * Neutrophils \> or = 1500/mm3, platelets \> or = 150.000/mm3 and haemoglobin \> or =10 g/dL. * Renal Function appropriate * Hepatic Function appropriate * Serum Calcium tight to albumine \< or = 1,25 x upper normal limit (UNL). * Nutritional status appropriate: weight loss \< 20% and albumine \> or = 35 g/L. * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Exclusion Criteria: * Metastatic disease. * Surgical treatment, radiotherapy and/or previous chemotherapy. * Another tumour locations in head and neck area different from larynx or hypo larynx. * Another stages different from III or IVa without distant metastasis and resectable disease. * Another previous scaly carcinoma * Diagnosis of another neoplasia in last 5 years, except cervix carcinoma in situ and/or basocellular cutaneous carcinoma adequately treated. * Active infection treated by ATB IV, including active tuberculosis and VIH. * Hypertension not controled defined as systolic \> or = 180 mm Hg and/or diastolic \> or =130 mm Hg at rest. * Pregnant/lactating women. * Systemic immune treatment, chronic and concomitant, or cancer hormone treatment. * Another antineoplastics concomitant treatments. * Coronary artery disease or history of heart attack in the last 12 months or high risk of arrythmia uncontrolled or cardiac insufficiency uncontrolled. * EPOC that required more than 3 hospitalizations in the last 12 months. * Active ulcus not controled. * Psychiatric illness/social situations that would limit compliance with study requirements * Drug abuse (except alcohol abuse) * Knowledge of Allergic to study treatment. * Previous treatment with Monoclonal antibodies. * Any experimental treatment in the previous 30 days to start the study.